Skip to main content
. 2022 Mar 10;2022:9226022. doi: 10.1155/2022/9226022

Figure 1.

Figure 1

Ligustrazine suppresses the production of profibrotic cytokines in hypoxia-induced PMCs. (a) MTT assay of PMCs under hypoxic conditions with different exposure time. Compared with the control, ∗P < 0.05 and ∗∗P < 0.01. (b) Western blot analysis of protein expression of profibrotic cytokines (VEGF and CTGF) in hypoxia-induced PMCs treated with different concentrations of ligustrazine for 24 h. (c, d) qRT-PCR analysis of mRNA levels of profibrotic cytokines (VEGF and CTGF) in hypoxia-induced PMCs treated with different concentrations of ligustrazine for 24 h. Compared with the control, ∗P < 0.05 and ∗∗P < 0.01. (e, f) ELISA analysis of supernatant levels of profibrotic cytokines (VEGF and CTGF) in hypoxia-induced PMCs treated with different concentrations of ligustrazine for 24 h. Compared with the control, ∗P < 0.05 and ∗∗P < 0.01.